IMEIK(300896)2025-03-19 12:30Financial Performance - The company's operating revenue for 2024 reached ¥3,025,668,449.47, representing a 5.45% increase compared to ¥2,869,347,231.89 in 2023[20]. - Net profit attributable to shareholders for 2024 was ¥1,957,596,837.74, up by 5.33% from ¥1,858,475,302.54 in 2023[20]. - The net profit after deducting non-recurring gains and losses was ¥1,871,694,735.68, reflecting a 2.20% increase from ¥1,831,328,790.94 in 2023[20]. - The net cash flow from operating activities decreased by 1.38% to ¥1,927,174,523.41 from ¥1,954,070,643.13 in 2023[20]. - Total assets at the end of 2024 amounted to ¥8,340,486,256.64, a 21.72% increase from ¥6,852,360,636.01 in 2023[20]. - Net assets attributable to shareholders increased by 22.83% to ¥7,797,060,228.15 from ¥6,347,942,275.99 in 2023[20]. - The basic earnings per share for 2024 was ¥6.50, a 15.69% increase from ¥5.84 in 2023[20]. - The diluted earnings per share also stood at ¥6.50, reflecting a 15.69% increase from ¥5.84 in 2023[20]. - The company reported a total of ¥85,902,102.06 in non-recurring gains for 2024, compared to ¥27,146,511.60 in 2023[26]. Market Position and Growth - The Chinese medical beauty market is expected to grow at a rate of approximately 10% in 2024, driven by increasing penetration and diversified quality demands[1]. - The company has maintained the number one market share in the domestic hyaluronic acid-based dermal fillers market since 2018[3]. - The penetration rate of medical beauty in China increased from 2.4% in 2014 to 4.5% in 2023, indicating significant growth potential compared to developed countries with rates around 17.8%[55]. - The domestic medical beauty market is expected to grow at a rate of approximately 10% in 2024, driven by increasing consumer income and acceptance of medical beauty services[54]. - The Chinese medical beauty market is projected to reach ¥638.2 billion by 2030, with a compound annual growth rate (CAGR) of 14.5% from 2021 to 2030[125]. Research and Development - The company invested approximately 30,368,400 CNY in R&D, accounting for 10.04% of operating revenue[45]. - The company holds 163 valid authorized patents, including 49 invention patents[45]. - The company is actively pursuing market expansion through new product development and acquisitions, enhancing its competitive position in the aesthetic medical field[78][82]. - The company is in the clinical trial phase for several new products, including the second-generation implant line and medical sodium hyaluronate gel, aimed at expanding market share and revenue[82][83]. - The company is focusing on the development of recombinant proteins and peptides in the biomedical field to enhance its product offerings[129]. Corporate Governance - The company’s actual governance situation complies with relevant laws and regulations, ensuring a robust internal management structure[145]. - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management[150]. - The company maintains an independent operational structure, with no interference from controlling shareholders in decision-making[147]. - The company has independent financial management, with no shared bank accounts with controlling shareholders[162]. - The company’s governance structure complies with the requirements of the Corporate Governance Code and relevant regulations[155]. Investment and Funding - The total fundraising amount raised by the company was RMB 357,175.40 million, with a net amount of RMB 343,513.38 million after deducting issuance costs of RMB 13,662.02 million[111]. - The company has achieved a usage rate of 60.49% for the total raised funds, with 3.77% of the total amount remaining unused[109]. - The company has committed to invest a total of 193,494.22 million in various projects, with 122,241.77 million allocated to new research and development centers[114]. - The company has raised 85,565.26 million for investment and acquisition purposes, enhancing its market position[114]. - The company plans to use up to RMB 12 billion of temporarily idle raised funds for cash management, including purchasing structured deposits and large certificates of deposit[116]. Product Development and Innovation - The company has launched 11 Class III medical device products, including "Yimei," "Aifulai," "Baonida," "Haitai," "Jinlian," and "Rubai Tianzi," focusing on skin injection, filling, and treatment[39]. - The company emphasizes technological innovation, establishing a product technology transformation platform for biodegradable new materials[4]. - The company has successfully commercialized a series of skin fillers based on sodium hyaluronate and polylactic acid, with ongoing development of recombinant proteins and peptides[61]. - The company is exploring acquisition opportunities to enhance its product portfolio, targeting firms with complementary technologies[171]. - The company plans to enhance brand image and expand market presence by focusing on technological innovation and customer needs in 2025[131]. Employee and Management - The total number of employees at the end of the reporting period is 1,223, including 793 at the parent company and 430 at major subsidiaries[194]. - The company has 542 sales personnel, 293 technical staff, and 229 production workers, contributing to a diverse professional structure[195]. - The company established a comprehensive performance management system linked to a flexible compensation structure, ensuring employee interests are safeguarded[196]. - In 2024, the company trained 1,041 employees, with an average training duration of 50.05 hours per employee[198]. - The total remuneration paid to directors, supervisors, and senior management in 2024 amounted to CNY 17.088 million, including CNY 560,400 for independent directors[184].